Key insights
- Johnson & Johnson will acquire Atraverse Medical to expand its cardiac ablation solutions. The deal, expected to close in Q2 2026, adds Atraverse's left-heart access and radiofrequency technology to JNJ's portfolio. Financial terms were not disclosed. This is unlikely to have a significant impact on the broader US equity market.
Investing.com -- Johnson & Johnson (NYSE:JNJ) announced Friday it has entered into a definitive agreement to acquire Atraverse Medical, Inc., a privately-held medical device company that develops left-heart access and radiofrequency technology.
Atraverse Medical manufactures the HOTWIRE Transseptal Access System, an FDA-cleared radiofrequency guidewire and generator system used for accessing the left atrium during atrial fibrillation procedures. The system has been used in nearly 3,000 clinical procedures and features impedance-sensing automatic energy shutoff, compatibility with multiple sheaths, and tip visibility under intracardiac echocardiography.
The acquisition is intended to expand Johnson & Johnson’s cardiac ablation solutions portfolio, providing electrophysiologists with tools for treating patients with atrial fibrillation and other cardiac arrhythmias.
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions. Financial terms of the transaction were not disclosed.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.